In contrast, scenarios driven by the binding of AnxA1 to FPRs have associated high AnxA1 levels with poor patient survival and progression in metastatic and triple-negative breast cancers (TNBC) [93]. Here, ANXA1 is linked to triple-negative breast carcinoma.